SCHEMBL30837783

SCHEMBL30837783

COc1ccc(Cn2c(=O)c3cc(CNC(C)=O)ccc3n(C3CCOCC3)c2=O)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 9/20 0.73
PDE7B Q9NP56 4/20 0.54
PDE8A O60658 2/20 0.54
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PDE1A P54750 1/20 0.42
PDE1B Q01064 1/20 0.42
PDE1C Q14123 1/20 0.42
TP53 P04637 3/20 0.41
RXFP1 Q9HBX9 1/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2683480 1.00 PDE7A (0.73) PDE7APDE7BPDE8AALDH1A1KDM4E
SCHEMBL2682202 0.93 PDE7A (0.64) PDE7APDE7BPDE8AALDH1A1KDM4E
SCHEMBL30837794 0.93 PDE7A (0.64) PDE7APDE7BPDE8AALDH1A1KDM4E
SCHEMBL134836 0.90 PDE7A (0.73) PDE7APDE7BPDE8AALDH1A1KDM4E
SCHEMBL100671 0.89 PDE7A (0.77) PDE7APDE7BPDE8AALDH1A1TP53
SCHEMBL585427 0.88 PDE7A (0.76) PDE7APDE7BPDE8AALDH1A1KDM4E
SCHEMBL30837805 0.88 PDE7A (0.91) PDE7APDE7BPDE8ATP53RXFP1
SCHEMBL99906 0.88 PDE7A (0.91) PDE7APDE7BPDE8ATP53RXFP1
SCHEMBL581703 0.88 PDE7A (0.60) PDE7APDE7BPDE8AALDH1A1KDM4E
SCHEMBL30837940 0.88 PDE7A (0.60) PDE7APDE7BPDE8AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed